|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
Serum Mac-2-binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B related cirrhosis.
|
31574141 |
2020 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
<b>:</b> We sought to compare the impact upon grip strength (GS) between the Mac-2 binding protein glycosylation isomer (M2BPGi) and the Fibrosis-4 (FIB4) index in chronic liver disease (CLD) patients (<i>n</i> = 376: 171 males and 205 females, and 137 liver cirrhosis (LC) cases (36.4%)).
|
31480612 |
2019 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
Advanced age, low grip strength, hepatic encephalopathy, and high WFA<sup>+</sup> -M2BP might be risk factors for LSMM in liver cirrhosis patients.
|
30623996 |
2019 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
AlteredExpression |
BEFREE |
Initial M2BPGi level after diagnosis of liver cirrhosis based on liver biopsy was on average 3.4, and the most recent M2BPGi level under observation was on average 4.3.
|
31392502 |
2019 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
To determine whether or not the WFA<sup>+</sup> -M2BP value was associated with a progression of fibrosis among cirrhosis, this study examined WFA<sup>+</sup> -M2BP levels between patients with cirrhosis in the decompensated and compensated groups.
|
29737582 |
2018 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
For predicting cirrhosis (F4) and advanced liver fibrosis (≥ F3), M2BPGi had higher areas under the curve (AUCs; 0.93, respectively) with cutoff COIs of 1.84 and 1.67, respectively, than for the four conventional markers for fibrosis.
|
30128700 |
2018 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
Serum WFA<sup>+</sup> -M2BP is a reliable predictor of liver function and prognosis in LC and could be incorporated into clinical surveillance strategies for LC patients, especially those with HBV infection.
|
29607614 |
2018 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
Among eight fibrosis markers/indices, WFA<sup>+</sup> -M2BP yielded the second highest AUC (0.832) and the highest predictive accuracy (82.2%) to diagnose cirrhosis.
|
29274190 |
2018 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
AlteredExpression |
BEFREE |
WFA+ -M2BP level was found to be significantly increased in the fibrotic NASH and NASH cirrhosis groups compared to healthy controls and those with early NAFLD after adjusting for age, gender and BMI.
|
30161179 |
2018 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
The WFA<sup>+</sup> -M2BP marker was superior to AFP in differentiating early-stage HCC (BCLC stages 0 and A) from cirrhosis with AUROC of 0.80 (95% CI, 0.68-0.91; P < 0.001) and 0.73 (95% CI, 0.60-0.86; P = 0.002), respectively.
|
29732647 |
2018 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
GeneticVariation |
BEFREE |
Serum WFA<sup>+</sup> -M2BP values were retrospectively evaluated in 112 treatment-naïve patients with HBV-related chronic hepatitis and cirrhosis who had undergone liver biopsy at our hospital.
|
27029022 |
2017 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
Biomarker |
BEFREE |
In conclusion, serum WFA+-M2BP was most useful for the diagnosis of significant fibrosis, advanced fibrosis and cirrhosis in NAFLD patients.
|
28369100 |
2017 |
|
LGALS3BP
|
Liver Cirrhosis
|
0.400 |
AlteredExpression |
BEFREE |
In patients without cirrhosis (n=1087), WFA<sup>+</sup> -M2BP levels ≥1.8 were associated with a higher risk of HCC development (P<.001 by log-rank test), whereas WFA<sup>+</sup> -M2BP levels ≥1.8 tended to be associated with a higher risk of HCC development in patients with cirrhosis (n=236) (P=.073 by log-rank test).
|
27973711 |
2017 |